Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
INViCARE logo — We Make It Eternal

INViCARE

We Make It Eternal

Founded 2017 Canada Montreal, Canada 3 employees Biotechnology, Health Care +2

General Information

Company Name INViCARE
Founded Year 2017
Location Canada Montreal, Canada
Employees 3
Industries Biotechnology, Health Care, Manufacturing +1
Social

BounceWatch is an independent company data service, not affiliated with INViCARE. To contact INViCARE, visit invicare.ca.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does INViCARE compare?

A PDF of INViCARE and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting INViCARE soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About INViCARE

INViCARE, a Canadian startup founded in 2017, is making significant strides in the healthcare industry with its cutting-edge approach to implant care. The company's slogan, "We Make It Eternal," encapsulates its mission to enhance the longevity and safety of medical implants.

Specializing in Biotechnology, Health Care, Manufacturing, and Medical Devices, INViCARE is pioneering the development of nano-crystalline biomaterials. Their innovative products are designed to prevent and treat implant infections, addressing a critical need in medical treatments.

Notably, INViCARE's flagship product is a decontamination hydrogel specifically tailored for dental implant hygiene, offering a novel solution for infection control. With headquarters in Canada and a strategic focus on revolutionizing implant care, the company remains well-positioned in the market.

Though there is no recent investment information available, INViCARE's unique technology and industry focus make it a promising prospect for future investment opportunities in the healthcare sector.

Business keywords: startups, biomaterials, implant care, nanotechnology, dental implants, infection prevention, crystalline biomaterials, dental hygiene, biomedical engineering

No funding data available for INViCARE yet.

INViCARE Alternatives & Competitors

View All Alternatives
INViCARE vs
Nanovis
Nanovis United States

Best in class nanotechnology surface company.

Venture round
23 employees
Biotechnology, Health Care
INViCARE vs
DTI Implant Systems
DTI Implant Systems Turkey

"We Produce Science"

23 employees
Health Care, Manufacturing
INViCARE vs
T&RBiofab
T&RBiofab Korea South

Where bioprinting, stem cells and biomaterials meet to change people's lives

Post-IPO Equity
30 employees
Biotechnology, Manufacturing
View all alternatives

FAQ About INViCARE

We Make It Eternal
INViCARE was founded in 2017.
INViCARE is headquartered in Montreal, Canada.
INViCARE operates in Biotechnology, Health Care, Manufacturing and Medical Devices. Its work centres on startups, biomaterials, implant care and nanotechnology.
INViCARE has approximately 3 employees.
Top alternatives and competitors to INViCARE include Nanovis, DTI Implant Systems, T&RBiofab, Southern Implants, Neocis. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
INViCARE and Nanovis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for INViCARE, https://bouncewatch.com/company/invicare, updated 28 July 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout